… profile of pembrolizumab and evaluate its future development. … pembrolizumab, the first
anti–PD-1 agent to be approved by the US Food and Drug Administration (FDA). Pembrolizumab …

… ), pembrolizumab induced ORRs of 19–25%. Based on these results, pembrolizumab was …
-antigens, had better responses to pembrolizumab. In malignancies including lymphomas and …

Background We assessed the efficacy and safety of programmed cell death 1 (PD-1) inhibition
with pembrolizumab in patients with advanced non–small-cell lung cancer enrolled in a …

… Pembrolizumab has received its first global approval for the … in the development of
pembrolizumab leading to this first … important differences in pembrolizumab clearance in patients …

… safety profile associated with pembrolizumab in patients with early triple-negative breast
cancer. Whether the addition of pembrolizumab to neoadjuvant chemotherapy would …

… mg of pembrolizumab or placebo every 3 weeks for 4 cycles, followed by pembrolizumab or
… Crossover to pembrolizumab monotherapy was permitted among the patients in the placebo…

… The response rate was improved with pembrolizumab … two pembrolizumab groups. Rates
of treatment-related adverse events of grade 3 to 5 severity were lower in the pembrolizumab …

… pembrolizumab, if safety criteria were met. There was no preplanned crossover from the
pembrolizumab … disease progression for patients in the pembrolizumab group. Patients in either …

… treatment, or the completion of 2 years of pembrolizumab therapy. … pembrolizumab group
who had a complete response could discontinue treatment if they had received pembrolizumab …

Background Pembrolizumab has efficacy in programmed death ligand 1 (PD-L1)–positive
metastatic or unresectable cervical cancer that has progressed during chemotherapy. We …